Abstract
Background: Systemic bacterial infection carries a high risk of mortality in critical care patients. Improvements in diagnostic procedures are required for effective management of sepsis. Recently, the soluble CD14 subtype, or presepsin, has been suggested as a reliable marker of sepsis, and we set out to compare its diagnostic performance with that of procalcitonin (PCT). We focused on a cohort of septic patients who, during their hospitalization, relapsed after a period of clinical relief from symptoms.
Methods: In total 21 adult patients were studied during their hospitalization in the Critical Care Unit of Policlinico Umberto I hospital; 74 plasma samples were collected at multiple time points, and presepsin levels were measured using a PATHFAST® analyzer.
Results: Presepsin and PCT were significantly lower in healthy controls than in sepsis or severe sepsis (p<0.001), both enabled a significant difference to be detected between systemic inflammatory response syndrome (SIRS) and severe sepsis (p<0.05). The area under the curve (AUC) calculated from the receiver operating characteristic (ROC) curve analysis was 0.888 for presepsin and 0.910 for PCT. In those patients in whom a clinical recurrence of sepsis was observed, while PCT levels normalized during the transient remission phase, presepsin levels (>1000 pg/mL) remained high.
Conclusions: This study confirms the importance of monitoring a combination of several biomarkers in order to obtain a reliable diagnosis. Maximal presepsin levels could alert clinicians not to suspend antibiotic treatments and to carefully monitor septic patients’ state of health, even after clinical symptoms have disappeared and PCT levels returned to normal.
Acknowledgments
We thank Anna Forster for linguistic assistance.
Conflict of interest statement
Authors’ conflict of interest disclosure: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Financial support: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004;8:222–6.10.1186/cc2917Search in Google Scholar
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244–50.10.1097/01.CCM.0000261890.41311.E9Search in Google Scholar
3. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637–44.10.1001/archinte.164.6.637Search in Google Scholar
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96.10.1097/01.CCM.0000217961.75225.E9Search in Google Scholar
5. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524–8.10.1016/j.annemergmed.2004.12.006Search in Google Scholar
6. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637–42.10.1097/01.CCM.0000132904.35713.A7Search in Google Scholar
7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.10.1086/421997Search in Google Scholar
8. Haubitz S, Mueller B, Schuetz P. Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies. Expert Rev Respir Med 2013;7:145–57.10.1586/ers.13.6Search in Google Scholar
9. Herrmann W, Ecker D, Quast S, Klieden M, Rose S, Marzi I. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 2000;38:41–6.10.1515/CCLM.2000.007Search in Google Scholar
10. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997;40:1250–6.10.1002/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-ASearch in Google Scholar
11. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139–47.10.1056/NEJM200010193431602Search in Google Scholar PubMed
12. Reinhart K, Meisner M, Brinkhorst FM. Markers for sepsis diagnosis: What is useful? Crit Care Clin 2006;22:503–19.10.1016/j.ccc.2006.03.003Search in Google Scholar PubMed
13. Tong HS, Liu YS, Wen Q, Tang YQ, Yuan FF, Su L. Serum procalcitonin predicting mortality in exertional heatstroke. Emerg Med J 2012;29:113–7.10.1136/emj.2010.107680Search in Google Scholar PubMed
14. Hausfater P, Hurtado M, Pease S, Juillien G, Lvovschi VE, Salehabadi S, et al. Is procalcitonine a marker of critical illness in heatstroke? Intensive Care Med 2008;34: 1377–83.10.1007/s00134-008-1083-ySearch in Google Scholar PubMed
15. Nylén ES, Al Arifi A, Becker KL, Snider RH Jr, Alzeer A. Effect of classic heatstroke on serum procalcitonin. Crit Care Med 1997;25:1362–5.10.1097/00003246-199708000-00024Search in Google Scholar PubMed
16. Balci C, Sivaci R, Akbulut G, Karabekir HS. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res 2009;37:1709–17.10.1177/147323000903700606Search in Google Scholar PubMed
17. Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T, et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 2009;66: 243–9.10.1097/TA.0b013e31817c966fSearch in Google Scholar PubMed
18. Mussap M, Degrandi R, Cataldi L, Fanos V, Plebani M. Biochemical markers for the early assessment of neonatal sepsis: the role of procalcitonin. J Chemother 2007;19(Suppl 2):35–8.10.1080/1120009X.2007.11782442Search in Google Scholar PubMed
19. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50: 23–36.10.3109/10408363.2013.764490Search in Google Scholar PubMed PubMed Central
20. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011;24(Suppl 2):12–4.10.3109/14767058.2011.601923Search in Google Scholar PubMed
21. Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012;25(Suppl 5):51–3.10.3109/14767058.2012.717462Search in Google Scholar PubMed
22. Camussi G, Montrucchio G, Tobias PS. Lipopolysacchararide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol 1995;155:316–24.10.4049/jimmunol.155.1.316Search in Google Scholar
23. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17:764–9.10.1007/s10156-011-0254-xSearch in Google Scholar PubMed
24. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012;18: 891–7.10.1007/s10156-012-0435-2Search in Google Scholar PubMed
25. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011;412:2157–61.10.1016/j.cca.2011.07.024Search in Google Scholar PubMed
26. Bachetoni A, Mariani P, D’Alessandro M, Baiano V, Appodia C, Collepardo D, et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. Transplant Proc 2007;39:2008–9.10.1016/j.transproceed.2007.05.079Search in Google Scholar PubMed
27. ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovate therapies in sepsis. Crit Care Med 1992;20:867–74.Search in Google Scholar
28. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physician/Society of Critical Care Medicine. Chest 1992;101:1644–55.10.1378/chest.101.6.1644Search in Google Scholar PubMed
29. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.10.1097/01.CCM.0000298158.12101.41Search in Google Scholar PubMed
30. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546–54.10.1056/NEJMoa022139Search in Google Scholar PubMed
31. Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin 2008;24(3 Suppl):1–47.10.1016/j.ccc.2008.04.002Search in Google Scholar PubMed
32. Palmiere C, Mussap M, Bardy D, Cibecchini F, Mangin P. Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities. Int J Legal Med 2013;127:799–808.10.1007/s00414-012-0804-5Search in Google Scholar PubMed
33. Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yamasaki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care 2008;12(Suppl 2):194.10.1186/cc6415Search in Google Scholar
34. Agilli M, Sener I, Yesildal F, Honca T, Aydin I, Akgul EO, et al. A new marker for the diagnosıs of sepsis: presepsin. J Invest Biochem 2012;1:55–7.10.5455/jib.20120521073837Search in Google Scholar
©2015 by De Gruyter
